ST-002 is under clinical development by SteroTherapeutics and currently in Phase II for Cushing’s Syndrome. According to GlobalData, Phase II drugs for Cushing’s Syndrome have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ST-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ST-002 overview
ST-002 (fluasterone) is under development for the treatment of Cushing’s syndrome. It acts by targeting glucose-6 phosphate dehydrogenase.
It was also under development for the treatment of hyperlipidemia, actinic (solar) keratosis, multiple sclerosis, cardiovascular disease, breast cancer, prostate cancer, type 2 diabetes, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, colon cancer, liver cancer and skin cancer. It is administered orally and topically.
It was also under development for the treatment of Duchene muscular dystrophy (DMD).
SteroTherapeutics overview
Stero Therapeutics, is a pharmaceutical company that focused on developing novel therapies for diseases with significant unmet needs. The company is headquartered in United States.
For a complete picture of ST-002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
